Results 91 to 100 of about 28,326 (256)
Journal of Laboratory MedicineCirculating tumor DNA (ctDNA) assays play an increasingly important role in cancer management. A new version of TruSight Oncology 500 (TSO500) ctDNA, v2, was recently released, and the recommended DNA input was decreased to 20 ng from 30 ng in the prior ...
Lee Cheonghwa +3 more
doaj +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms ...
Christine Worthington +105 more
wiley +1 more source
Dynamics of ctDNA in patients with NSCLC
Annals of Oncology, 2019 Abstract Background For many years, researchers have tried to find more effective ways to find out if a person has cancer, and find it at an early stage, when it is most curable. One idea that is gaining popularity is called liquid biopsy. Methods From 2016 to 2018 we studied 1050 patients with non-small-cell lung cancer (NSCLC).
A.S. Zhabina +4 more
openaire +1 more source
International Journal of Cancer, EarlyView.While current guidelines recommend the analysis of established cancer driver genes in brain metastases, little is known about its real‐life implementation. This multicenter study revealed an upward trend in the profiling rates of surgically treated brain metastases over the past decade, with up to 60% of brain metastases samples undergoing analysis ...
Maria Nikolaeva +25 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT The incidence of human papillomavirus‐positive (HPV+) oropharyngeal cancer (OPC) has increased rapidly, and HPV early antigen serology has been proposed as a scalable and cost‐effective early detection test. HPV seropositivity can precede clinical presentation of OPC by several years, so additional surveillance procedures may be necessary to ...
Lucas Penny +23 more
wiley +1 more source
iNew Medicine, EarlyView.ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid +4 more
wiley +1 more source
Expanding the clinical uses of ctDNA
Practical oncology, 2021 The majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal with the detection of mutations. The analysis of cfDNA is often discussed in the context of the noninvasive detection of mutations that lead to resistance mechanisms and therapeutic and disease monitoring in cancer patients.
openaire +1 more source
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
Journal of Hematology & Oncology, 2019 Background Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation sequencing technologies.
Hitendra Patel +7 more
doaj +1 more source
Integrated one‐pot CRISPR‐Cas detection: Addressing strategies and future prospects
Interdisciplinary Medicine, EarlyView.Integrated one‐pot CRISPR‐Cas detection significantly simplifies workflows, reduces cross‐contamination risks, and shortens turnaround times, making it highly suitable for point‐of‐care testing (POCT) and resource‐limited settings. Key challenges include system compatibility issues between Cas proteins and isothermal amplification, limited multiplexing
Jian Zhou +6 more
wiley +1 more source
Detection of Hypomethylation in Long-ctDNA
Clinical Chemistry, 2022 Simon A Joosse, Klaus Pantel
openaire +2 more sources